Status:
RECRUITING
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Benzodiazepine Withdrawal
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We hypothesise that a short-term intervention by dispensing pharmacists is feasible and relatively easy to implement, and that it could have an impact on the deprescribing of BZD/Z in adult patients. ...
Detailed Description
In France, the prevalence of use of benzodiazepines (BZDs) and related drugs (Z-drugs: zolpidem, zopiclone) (BZD/Z) was estimated at 13.4% in 2015, and 15% of new users had a first prescription exceed...
Eligibility Criteria
Inclusion
- Continuous treatment (at least once daily) with BZD/Z for at least 6 months, after verification of 6 months' supply.
- Signed informed consent
- Patient able to understand the survey and complete a questionnaire in French.
- Affiliation with the French social security system
Exclusion
- Concomitant treatment with:
- The following oral antipsychotics: risperidone, olanzapine, aripiprazole, quetiapine, clozapine, haloperidol, flupentixol, pimozide, chlorpromazine, sulpiride, zuclopenthixol, loxapine, cyamemazine (\>100mg/D), sulpiride (\>150mg/D),
- Injectable medium- and long-acting antipsychotics
- Thymoregulatory treatment with lithium
- Treatments for alcohol use disorders: baclofen, nalmefene, naltrexone, acamprosate, disulfiram
- Opiate substitution treatments: buprenorphine, methadone
- Anti-epileptic drugs
- History of convulsions or epilepsy
- History of gabaergic withdrawal accidents: delirium tremens, confusional syndrome requiring specialist treatment (hospitalisation, specialist consultation), epileptic seizures, etc.
- Patients suffering from cancer
- Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons: pregnant women, women in childbirth, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).
Key Trial Info
Start Date :
December 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06446349
Start Date
December 2 2024
End Date
December 1 2026
Last Update
December 11 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacie Riffard Annonay
Annonay, France, 07100
2
Pharmacie du Village
Auriol, France, 13390
3
Pharmacie des Champs Dolent
Beauvais, France, 60000
4
Pharmacie Troisgros
Cap-d'Ail, France, 06320